Partnership Forums
AMCP Partnership Forums bring together key decision-makers in various managed care industries to discuss and collaborate on strategies to drive efficiency and improve patient outcomes in an interactive environment. Designed to address current market challenges and opportunities, AMCP Partnership Forums also:
- Take a proactive, collaborative approach to solving critical issues and challenges.
- Gain consensus on removing barriers to improve patient care and optimize value for all stakeholders.
- Provide opportunities for payers, manufacturers, patients, and other stakeholders to collaborate on common goals and interests and create actionable results.
- Experience high visibility among industry stakeholders and policymakers.
Partnership Forums:
June 24-25, 2025
A Unified Approach: Advancing Precision Medicine in Oncology
Description
Despite its promise, significant gaps persist slowing the widespread adoption of precision medicine, particularly around clinical and payer decision-making related to biomarker testing and targeted therapies. Challenges such as misalignment between managed care policies and clinical guidelines, reimbursement barriers, and health equity concerns. Addressing these gaps is essential to ensure precision medicine can be effectively implemented to benefit diverse patient populations. AMCP's Partnership Forum will bring together key stakeholders to explore strategies for advancing precision medicine. Attendees will engage in discussions on best practices for integrating biomarker testing and targeted therapies into clinical and payer decision-making while identifying challenges and actionable solutions. The meeting is part of a broader precision medicine initiative AMCP is undertaking to shape policy, enhance collaboration, and improve healthcare outcomes.
Nov. 12-13, 2024
Closing the Gap in Real-World Evidence Use: A Collaborative Approach for Health Care Transformation
Program Guide
Description
Real-world evidence (RWE) is increasingly used to support epidemiologic studies, safety and effectiveness studies, and even contribute to clinical trials or as evidence included in regulatory submissions. However, RWE has a much less prominent role in payer decision-making, particularly due to challenges such as a lack of standards and guidelines for how to evaluate and use RWE, lack of experience in applying RWE to formulary decisions, and lack of understanding how RWE could be most impactful for payer decisions. AMCP is developing standards and resources to support RWE interpretation and application to formulary and medical policy decisions. These standards aim to align RWE definitions, improve the transparency in RWE generation, increase consistency in how sponsors develop and share RWE, and support the ongoing communication between payers and pharmaceutical manufacturers.
This Partnership Forum will convene multi-stakeholder experts to develop resources that will address barriers to RWE use in formulary decision-making through workshop and collaborative activities that will result in a set of RWE standards and tools to facilitate stakeholder communication and streamline the use of RWE.
Learn more about the AMCP Research Institute Real World Evidence (RWE) Initiative.
See proceedings and findings from this Partnership Forum.
Ongoing:
ADVISORY GROUP — Addressing Barriers to Value-Based Payment Models in Integrated Delivery Networks
Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.
ADVISORY GROUP — Substance Use Disorder: A Focus on Prescription Drug Use
Despite efforts to decrease the use of opioids, challenges remain. AMCP created multiple advisory groups beginning in 2015 recognizing the widespread and devastating nature of the opioid crisis. Over time, these groups addressed access to medications for treatment of substance use disorders and developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address substance use disorder.
ADVISORY GROUP — Health Disparities
Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. As part of AMCP's strategic priority on addressing health disparities and commitment to transition from awareness to action, AMCP is committed to leveraging managed care pharmacy to address disparities in benefit design, medication use and outcomes in underserved populations. This advisory group will build upon the recommendations put forth during AMCP's 2021 Partnership Forum and will provide guidance as AMCP works to create awareness on the role of managed care professionals in this area, identify partners, and develop tools and resources to aid managed care pharmacy transition from awareness to action.
ADVISORY GROUP — Digital Therapeutics
The role of digital therapeutics in preventing, managing, and treating medical conditions continues to evolve, offering the potential for therapeutic benefit. AMCP is committed to leveraging managed care pharmacy to continue to evolve the use of digital therapeutics to improve patient care and outcomes. This group will build upon the recommendations put forth during the previous AMCP Partnership Forums and provide guidance to AMCP in its efforts to establish the leadership role of managed care pharmacy professionals in this area, identify potential partners, and assist in the creation and dissemination of tools and resources to enhance the coverage and utilization of digital therapeutics.
